TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
出版年份 2023 全文链接
标题
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
作者
关键词
-
出版物
JOURNAL OF NANOBIOTECHNOLOGY
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-11-06
DOI
10.1186/s12951-023-02183-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings
- (2023) Pasquale Lombardi et al. Cancers
- Targeting Trop-2 in cancer: Recent research progress and clinical application
- (2023) Shuying Qiu et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
- (2023) Claudia Parisi et al. CANCER TREATMENT REVIEWS
- Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG
- (2022) Chihiro Ishiwatari-Ogata et al. Frontiers in Immunology
- TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer
- (2022) Michela Cortesi et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer
- (2022) Xinlin Liu et al. PHARMACOLOGY & THERAPEUTICS
- PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
- (2022) Xiaolu Yu et al. Journal for ImmunoTherapy of Cancer
- Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis
- (2022) Mengnan Zhao et al. Acta Pharmaceutica Sinica B
- Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
- (2022) Mythili Shastry et al. BREAST
- Ozoralizumab: First Approval
- (2022) Susan J. Keam DRUGS
- Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
- (2022) Yezhe Cheng et al. Frontiers in Oncology
- Nanobody—A versatile tool for cancer diagnosis and therapeutics
- (2021) Manman Liu et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy
- (2021) Sandeep Surendra Panikar et al. JOURNAL OF CONTROLLED RELEASE
- Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells
- (2021) Daisuke Okajima et al. MOLECULAR CANCER THERAPEUTICS
- Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma
- (2021) Ramona Erber et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Smart transformable nanoparticles for enhanced tumor theranostics
- (2021) Jinjin Chen et al. Applied Physics Reviews
- Calcium ion nanomodulators for mitochondria-targeted multimodal cancer therapy
- (2021) Pan Zheng et al. Asian Journal of Pharmaceutical Sciences
- Targeting apoptosis in cancer therapy
- (2020) Benedito A. Carneiro et al. Nature Reviews Clinical Oncology
- A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
- (2018) Gentry T. King et al. INVESTIGATIONAL NEW DRUGS
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway
- (2013) Ting Liu et al. PLoS One
- Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain
- (2013) Tilen Vidmar et al. PROTEIN EXPRESSION AND PURIFICATION
- The Trop-2 signalling network in cancer growth
- (2012) E Guerra et al. ONCOGENE
- Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway
- (2010) Rafael Cubas et al. Molecular Cancer
- High expression of TROP2 correlates with poor prognosis in pancreatic cancer
- (2008) D Fong et al. BRITISH JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started